On October, 24, 2024, the Office for Product Safety and Standards (OPSS) requested all stakeholders, including the cosmetics industry, academia, consumer associations, and others, to submit scientific information related to the safety assessment of the following cosmetic ingredients:
1. Prostaglandins and prostaglandin analogues
2. Alpha and beta-arbutin
3. Vitamin A
All scientific data submitted for safety assessment must include all relevant factors as specified in the Guidance for the Testing of Cosmetic Ingredients and Their Safety Evaluation.
Meanwhile, on October, 3, the UK notified the World Trade Oraganization (WTO) of the draft “The Cosmetic Products (Restriction of Chemical Substances) (No.2) Regulations 2024”, which aims to align UK cosmetics regulations with the European Union’s regulations regarding the safety of cosmetic ingredients. This amendment includes a ban on specific CMR (Carcinogenic, Mutagenic, or Reprotoxic) substances (65 types) and a limitation on the use of Kojic acid.
The transition periods for cosmetics containing banned CMR substances are as follows:
* Until April 20, 2025, products containing banned CMR substances can be placed on the market.
* Until October 20, 2025, products containing banned CMR substances can be sold on the market.
The transition periods for cosmetics containing Kojic acid are as follows:
* Until June 20, 2025, products containing Kojic acid can be placed on the market.
* Until November 1, 2025, products containing Kojic acid can be sold on the market.
This amendment, “The Cosmetic Product (Restriction of Chemical Substances)(No.2) Regulations 2024”, is scheduled to take effect on January 31, 2025.
Please refer to the link and attached document below.
1) OPSS, Call for Data: Safety of Cosmetic Ingredients
2) The Cosmetic Product (Restriction of Chemical Substances)(No.2) Regulations 2024
If you have any questions about medical device,
please contact us with the below
ra@jnmglobal.net
info@jnmglobal.net